Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on thiomersal
| GACVS report | Exposure | Outcome | Report link | |
| 2002 | June | DTP | Neurodevelopmental delay | https://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1 |
| HepB | Leukaemia | |||
| 2003 | June | HepB, other | General safety | https://www.who.int/vaccine_safety/committee/reports/wer7832.pdf?ua=1 |
| 2004 | Dec | Thiomersal (animal models) | Autism, neurodevelopmental delay | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8001.pdf?ua=1 |
| 2005 | June | Thiomersal | Mercury levels | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8028.pdf?ua=1 |
| 2008 | June | HepB | Mercury levels | https://www.who.int/vaccine_safety/committee/reports/wer8332.pdf?ua=1 |
| Thiomersal | Neuropsychological performance | |||
| 2012 | June | Thiomersal | Mercury levels, autism, neurodevelopmental delay, special risk groups | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8730.pdf?ua=1 |
DTP, diphtheria, tetanus and pertussis vaccine; HepB, hepatitis B vaccine.